ALK-Abelló is pleased to announce the marketing authorization of PRE-PEN® by Health Canada.

Catalent Pharma Solutions, Inc and Danish pharmaceutical company ALK-Abelló A/S have signed an agreement that will enable a substantial increase in Zydis® oral dissolving tablet production capacity dedicated to ALK-Abelló's immunotherapy products.

Danish pharmaceutical company Alk-Abello has entered into a strategic alliance with Schering-Plough to develop and commercialize its tablet-based allergy immunotherapies in the US, Canada and Mexico.

ALK-Abello said Monday it launched its tablet-based vaccine against grass pollen allergy, Grazax, in Germany. The launch of Grazax is the culmination of years of research and development at ALK-Abello, said Jens Bager, ALK-Abello's chief executive officer.

COPENHAGEN, Denmark, January 6 /PRNewswire-FirstCall/ -- According to preliminary results from a new study (GT-07) announced today, ALK-Abello's ground-breaking tablet-based allergy immunotherapy treatment reduces rhino-conjunctivitis (hay fever) symptoms by 37%, whilst reducing the need for symptom relieving medication by 41% (compared with placebo).